A Phase 1, Randomised, Double Blind, Placebo Controlled, 2-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Doses and Multiple Ascending Doses of ASLAN003 in Healthy Subjects

Trial Profile

A Phase 1, Randomised, Double Blind, Placebo Controlled, 2-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Doses and Multiple Ascending Doses of ASLAN003 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs ASLAN 003 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors ASLAN Pharmaceuticals
  • Most Recent Events

    • 02 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 30 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top